Literature DB >> 24639705

Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study.

Aalie Torabizadeh1, Fatemeh Vahidroodsari1, Zakieh Ghorbanpour1.   

Abstract

BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) is the most serious and potentially life-threatening iatrogenic complication associated with ovarian stimulation during Assisted Reproductive Technology (ART) protocols. OHSS typically is a result of ovarian expression of vascular endothelial growth factor (VEGF) which increases vascular permeability.
OBJECTIVE: Comparison of albumin and cabergoline in the prevention of OHSS.
MATERIALS AND METHODS: 95 high risk infertile women for OHSS (more than 20 follicles in both ovaries at day of Human Chorionic Gonadotropin (HCG) injection) were randomly divided into two groups. First group including 48 women received 10 unit intravenous albumin at starting oocyte retrieval, and second group including 47 women received 0.5 mg/day dopamine agonist (Cabergolin) at day of HCG injection till 8 days. The dosage of human Menopausal Gonadotropin (HMG) used, total number of follicles developed, number of oocytes retrieved, serum E2 concentrations during the luteal phase, development of ascites, number of embryos generated, clinical pregnancy rate, results of the in vitro fertilization-embryo transfer (IVF-ET) cycles and incidence and severity of any OHSS were evaluated.
RESULTS: There was evidence of a statistically significant reduction in the incidence of OHSS in the cabergolin group (53.7%) versus albumin group (46.3%) (p=0.04). But there was no significant difference of a reduction in severe OHSS (p=0.62). There was no difference in clinical pregnancy rate too.
CONCLUSION: Administration of cabergolin can prevent incidence of OHSS and does not appear to effect on its severity. REGISTRATION ID IN IRCT: IRCT138706281217N4.

Entities:  

Keywords:  Albumin; Assistedreproductivetechnology(ART); Cabergolin; Ovarianhyperstimulationsyndrome (OHSS)

Year:  2013        PMID: 24639705      PMCID: PMC3941342     

Source DB:  PubMed          Journal:  Iran J Reprod Med        ISSN: 1680-6433


  27 in total

1.  Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study.

Authors:  P Humaidan; L Bungum; M Bungum; C Yding Andersen
Journal:  Reprod Biomed Online       Date:  2006-08       Impact factor: 3.828

2.  Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.

Authors:  Arif Saylan; Dagistan Tolga Arioz; Tulay Koken; Husniye Dilek; Filiz Saylan; Mehmet Yilmazer
Journal:  Acta Obstet Gynecol Scand       Date:  2010-05       Impact factor: 3.636

3.  Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome.

Authors:  C D Chen; H F Chen; H F Lu; S U Chen; H N Ho; Y S Yang
Journal:  Hum Reprod       Date:  2000-05       Impact factor: 6.918

Review 4.  Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane review.

Authors:  M Aboulghar; J H Evers; H Al-Inany
Journal:  Hum Reprod       Date:  2002-12       Impact factor: 6.918

5.  Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability.

Authors:  R Gómez; C Simón; J Remohí; A Pellicer
Journal:  Biol Reprod       Date:  2003-01-22       Impact factor: 4.285

6.  Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.

Authors:  Carlos Carizza; Vicente Abdelmassih; Soraya Abdelmassih; Pedro Ravizzini; Lister Salgueiro; Paulo Tudech Salgueiro; Lin Tao Jine; Peter Nagy; Roger Abdelmassih
Journal:  Reprod Biomed Online       Date:  2008-12       Impact factor: 3.828

7.  Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology.

Authors:  A La Marca; S Giulini; A Tirelli; E Bertucci; T Marsella; S Xella; A Volpe
Journal:  Hum Reprod       Date:  2006-10-27       Impact factor: 6.918

8.  Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.

Authors:  Raúl Gómez; Carlos Simón; José Remohí; Antonio Pellicer
Journal:  Endocrinology       Date:  2002-11       Impact factor: 4.736

9.  Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study.

Authors:  José Bellver; Elkin A Muñoz; Agustín Ballesteros; Sérgio Reis Soares; Ernesto Bosch; Carlos Simón; Antonio Pellicer; José Remohí
Journal:  Hum Reprod       Date:  2003-11       Impact factor: 6.918

10.  Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study.

Authors:  Z Shoham; A Weissman; A Barash; R Borenstein; M Schachter; V Insler
Journal:  Fertil Steril       Date:  1994-07       Impact factor: 7.329

View more
  5 in total

Review 1.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma Mourad; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30

2.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma M Mourad; Aihua Wang; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14

Review 3.  Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis.

Authors:  Jun-Liang Guo; Duo-Duo Zhang; Yue Zhao; Dan Zhang; Xi-Meng Zhang; Can-Quan Zhou; Shu-Zhong Yao
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

4.  Comparison of the Effectiveness of Various Medicines in the Prevention of Ovarian Hyperstimulation Syndrome: A Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Di Wu; Hao Shi; Yiping Yu; Ting Yu; Jun Zhai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-26       Impact factor: 5.555

Review 5.  Volume expanders for the prevention of ovarian hyperstimulation syndrome.

Authors:  Mohamed A Youssef; Selma Mourad
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.